JLGH Summer 2024 Recap
Q&A for Extended Learning
Q: Ultra-long-acting insulins are now available with similar efficacy to shorter acting formulations. What are some benefits of insulin degludec (U-100 and U-200) and insulin glargine (U-300)?
A: Insulin degludec (U-100 and U-200) results in decreased rates of nocturnal hypoglycemia in clinical trials and a duration of action of up to 42 hours. Insulin glargine (U-300) allows for decreased injection volumes and a duration of action of up to 36 hours.
Read the article.
Q: Henoch-Schönlein purpura (HSP) generally occurs in children and teens 3-15 years of age and presents as palpable purpura with acute abdominal pain. What is the treatment for HSP?
A: Supportive care includes having patients stay well hydrated, plus using NSAIDs for joint pain and prednisone for more concerning symptoms. Frequent monitoring of kidney function is important; kidney biopsy is warranted in severe cases.
Q: Why might we consider treating dyspareunia in women with antibiotics?
A: Up to 80% of women of reproductive age with dyspareunia may have an undiagnosed urinary tract infection (UTI). While patients who are perimenopausal and postmenopausal more often have genitourinary syndrome than UTI, 94% of women with UTI-associated dyspareunia respond positively to antibiotics.
Read the article.
Q: Penn Medicine economist Rachel Werner, MD, PhD, suggests four approaches to modifying health care’s value-based payment program to advance health equity. What might these include?
A: Create accountability for equity, account for social risk in performance management, financially support under-resourced providers, and address drivers of inequity.
|